sitagliptin + simvastatin

**Sitagliptin + simvastatin** is an oral fixed-dose combination of the dipeptidyl peptidase-4 inhibitor sitagliptin and the HMG-CoA reductase inhibitor simvastatin. It was developed by Merck as MK-0431D and marketed in the United States as **Juvisync** for adults for whom treatment with both agents was appropriate, including people with type 2 diabetes mellitus and dyslipidemia. Sitagliptin increases endogenous incretin activity by reversibly inhibiting DPP-4, improving glucose-dependent insulin secretion and suppressing glucagon; simvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and circulating LDL cholesterol. Juvisync was approved by the FDA in 2011 and Merck ceased US and Puerto Rico distribution on September 26, 2013 for business reasons. ([merck.com](https://www.merck.com/news/fda-approves-mercks-juvisync-sitagliptin-and-simvastatin-tablets-a-once-daily-therapy-for-patients-with-type-2-diabetes-who-need-to-lower-blood-sugar-and-cholesterol-known-risk-f/))

Brand names

Juvisync

Other names

simvastatin + sitagliptinsimvastatin/sitagliptinSITA/SIMVsitagliptin and simvastatinsitagliptin/simvastatin